CBIO: Major clinical data for oncology assets expected in 2027, with strong cash runway and global strategy
The company is advancing a robust oncology pipeline with a PD-1/VEGF bispecific and ADCs, supported by a global partnership and efficient clinical trial design. Major data readouts are expected in 2027, with strong financial resources and a focus on rapid progression to phase III studies.Based on C…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.